{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:47:36Z","timestamp":1785552456997,"version":"3.56.0"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Conservative treatment of human hydatidosis (cystic echinococcosis) with albendazole has improved significantly the prognosis of the disease. But its therapeutic effectiveness is 30 \u2013 70 %. There is some evidence that the effectiveness of albendazole can be enhanced by praziquantel but there is no strict recommendation for the use of praziquantel as part of long-term drug therapy for hydatidosis.<\/jats:p>\n                  <jats:p>The aim of the study was to evaluate the effectiveness of the combination of albendazole and praziquantel in patients with hepatic and\/or pulmonary hydatidosis.<\/jats:p>\n                  <jats:p>A total of 20 patients (aged 12 \u2013 70 years old) were included in the study for a 5-year period. Fourteen patients (70 %) were with hepatic hydatidosis, 4 (20 %) with pulmonary and 2 (10 %) with hepatic and pulmonary hydatidosis. They were treated with albendazole (15 mg\/kg\/day) and praziquantel (40 mg\/kg\/weekly) for 2 \u2013 9 one-month courses. The result of the therapy was followed using imaging (abdominal ultrasound, lung radiography, computed tomography) and serology.<\/jats:p>\n                  <jats:p>Seventeen (85 %) out of 20 patients showed evidence of response on imaging defined as improvement or cure of hydatid cysts. Seven (35 %) of the patients with multiple cystic echinococcosis took praziquantel once a week for 6 months. Only 3 patients (15 %) with multiple hydatidosis (2 with liver and 1 with pulmonary hydatidosis) failed to respond to the therapy with both drugs. No side effects have been reported by the patients.<\/jats:p>\n                  <jats:p>The combination of albendazole and praziquantel seems to be an option to improve the therapeutic effectiveness of the conservative treatment of cystic echinococcosis.<\/jats:p>","DOI":"10.2478\/helm-2023-0028","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T04:42:53Z","timestamp":1703565773000},"page":"221-226","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of hepatic and pulmonary hydatidosis with albendazole and praziquantel"],"prefix":"10.2478","volume":"60","author":[{"given":"G.","family":"Popova","sequence":"first","affiliation":[{"name":"Medical University of Plovdiv , Department of Infectious diseases , Parasitology and Tropical Medicine, Section of Parasitology, St. George University Hospital , Plovdiv , Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vuchev","sequence":"additional","affiliation":[{"name":"Medical University of Plovdiv , Department of Infectious diseases , Parasitology and Tropical Medicine, Section of Parasitology, St. George University Hospital , Plovdiv , Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Anichina","sequence":"additional","affiliation":[{"name":"University of Chemical Technology and Metallurgy , Sofia , Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"2026042808552310174_j_helm-2023-0028_ref_001","doi-asserted-by":"crossref","unstructured":"Alvela-Su\u00e1rez, L., Velasco-Tirado, V., Belhassen-Garcia, M., Novo-Veleiro, I., Pardo-Lledias, J., Romero-Alegr\u00eda, A, P\u00e9rez del Villar, L., Valverde-Merino, M.P., Cordero-S\u00e1nchez, M. (2014): Safety of the Combined Use of Praziquantel and Albendazole in the Treatment of Human Hydatid Disease. Am J Trop Med Hyg, 90(5): 819 \u2013 822. DOI: 10.4269\/ajtmh.13-0059","DOI":"10.4269\/ajtmh.13-0059"},{"key":"2026042808552310174_j_helm-2023-0028_ref_002","unstructured":"Ayles, H.M., Corbett, E.L., Taylor, I., Cowie, A.G., Bligh, J, Walmsley, K., Bryceson, A.D. (2002): A combined medical and surgical approach to hydatid disease: 12 years of experience at the Hospital for Tropical Diseases, London. Ann R Coll Surg Engl, 84(2): 100 \u2013 105"},{"key":"2026042808552310174_j_helm-2023-0028_ref_003","doi-asserted-by":"crossref","unstructured":"Bonifacino, R., Carter, S., Craig, P., Almeida, I., Da Rosa, D. (2000): Assessment of the immunological surveillance value of humoral and lymphocyte assays in severe human cystic echinococcosis. Trans R Soc Trop Med Hyg, 94(1): 97 \u2013 102. DOI: 10.1016\/s0035-9203(00)90455-3","DOI":"10.1016\/S0035-9203(00)90455-3"},{"key":"2026042808552310174_j_helm-2023-0028_ref_004","doi-asserted-by":"crossref","unstructured":"Brunetti, E., Kern P., Vuitton, D.A., Writing Panel for the WHO-IWGE. (2010): Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop, 114 (1): 1 \u2013 16. DOI: 10.1016\/j.actatropica.2009.11.001","DOI":"10.1016\/j.actatropica.2009.11.001"},{"key":"2026042808552310174_j_helm-2023-0028_ref_005","doi-asserted-by":"crossref","unstructured":"Bygott, J.M., Chiodini, P.L. (2009): Praziquantel: Neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? Acta Trop, 111(2): 95 \u2013 101. DOI: 10.1016\/j.actatropica.2009.04.006","DOI":"10.1016\/j.actatropica.2009.04.006"},{"key":"2026042808552310174_j_helm-2023-0028_ref_006","doi-asserted-by":"crossref","unstructured":"Cobo, F., Yarnoz, C., Sesma, B., Fraile, P., Aizcorbe, M., Trujillo, R., Diaz-De-Lia\u00f1o, A., Ciga, M.A. (1998): Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by Echinococcus granulosus. Trop Med Int Health, 3(6): 462 \u2013 466. DOI: 10.1046\/j.1365-3156.1998.00257.x","DOI":"10.1046\/j.1365-3156.1998.00257.x"},{"key":"2026042808552310174_j_helm-2023-0028_ref_007","unstructured":"European Centre for Disease Prevention and Control. (2022): Echinococcosis. In: ECDC. Annual epidemiological report for 2020. Stockholm: ECDC"},{"key":"2026042808552310174_j_helm-2023-0028_ref_008","doi-asserted-by":"crossref","unstructured":"Haralabidis, S., Diakou, A., Frydas, S., Papadopoulos, E., Mylonas, A., Patsias, A., Roilides, E., Giannoulis, E. (2008): Long-term evaluation of patients with hydatidosis treated with albendazole and praziquantel. Int J Immunopathol Pharmacol, 21(2): 429 \u2013 435. DOI: 10.1177\/039463200802100223","DOI":"10.1177\/039463200802100223"},{"key":"2026042808552310174_j_helm-2023-0028_ref_009","doi-asserted-by":"crossref","unstructured":"Homeida, M., Leahy, W., Copeland, S., Ali, M.M., Harron, D.W. (1994): Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol, 88(5): 551 \u2013 559. DOI: 10.1080\/00034983.1994.11812903","DOI":"10.1080\/00034983.1994.11812903"},{"key":"2026042808552310174_j_helm-2023-0028_ref_010","doi-asserted-by":"crossref","unstructured":"Jamshidi, M., Mohraz, M., Zangeneh, M., Jamshidi, A. (2008): The effect of combination therapy with albendazole and praziquantel on hydatid cyst treatment. Parasitol Res, 103(1): 195 \u2013 199. DOI: 10.1007\/s00436-008-0954-z","DOI":"10.1007\/s00436-008-0954-z"},{"key":"2026042808552310174_j_helm-2023-0028_ref_011","doi-asserted-by":"crossref","unstructured":"Kern, P. (2006): Medical treatment of echinococcosis under the guidance of Good Clinical Practice (GCP\/ICH). Parasitol Int, 55 Suppl:S273 \u2013 S282. DOI: 10.1016\/j.parint.2005.11.040","DOI":"10.1016\/j.parint.2005.11.040"},{"key":"2026042808552310174_j_helm-2023-0028_ref_012","doi-asserted-by":"crossref","unstructured":"Lima, R.M., Ferreira, M.A., de Jesus Ponte Carvalho, T.M., Dum\u00eat Fernandes, B.J., Takayanagui, O.M., Garcia, H.H., Coelho, E.B., Lanchote, V.L. (2011): Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. Br J Clin Pharmacol, 71(4): 528 \u2013 535. DOI: 10.1111\/j.1365-2125.2010.03874.x","DOI":"10.1111\/j.1365-2125.2010.03874.x"},{"key":"2026042808552310174_j_helm-2023-0028_ref_013","doi-asserted-by":"crossref","unstructured":"L\u00f6tsch, F., Naderer, J., Skuhala, T., Groger, M., Auer, H. Kaczirek, K., Waneck, F., Ramharter, M. (2016): Intra-cystic concentrations of albendazole-sulphoxide in human cystic echinococcosis: a systematic review and analysis of individual patient data. Parasitol Res, 115 (8): 2995 \u2013 3001. DOI: 10.1007\/s00436-016-5054-x","DOI":"10.1007\/s00436-016-5054-x"},{"key":"2026042808552310174_j_helm-2023-0028_ref_014","doi-asserted-by":"crossref","unstructured":"Masoom, S., Lari, S., Fattahi, A., Ahmadnia, N., Rajabi, M., NaderiKalat, M. (2018): Albendazole therapy in human lung and liver hydatid cysts: A 13-year experience. Clin Respir J, 12(3): 1076 \u2013 1083. DOI: 10.1111\/crj.12630","DOI":"10.1111\/crj.12630"},{"key":"2026042808552310174_j_helm-2023-0028_ref_015","doi-asserted-by":"crossref","unstructured":"Mcmanus, D., Zhang, W., Li, J., Bartley, P.B. (2003): Echinococcosis. Lancet, 362(9392): 1295 \u2013 1304. DOI: 10.1016\/S0140-6736(03)14573-4","DOI":"10.1016\/S0140-6736(03)14573-4"},{"key":"2026042808552310174_j_helm-2023-0028_ref_016","unstructured":"Mohamed, A., Yasawy, M., Karawi, M. (1998): Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology, 45(23): 1690 \u2013 1694"},{"key":"2026042808552310174_j_helm-2023-0028_ref_017","doi-asserted-by":"crossref","unstructured":"Moro, P., Schantz P. M. (2009): Echinococcosis: a review. Int J Infect Dis, 13(2): 125 \u2013 133. DOI: 10.1016\/j.ijid.2008.03.037","DOI":"10.1016\/j.ijid.2008.03.037"},{"key":"2026042808552310174_j_helm-2023-0028_ref_018","doi-asserted-by":"crossref","unstructured":"Nazligul, Y., Kucukazman, M., Akbulut, S. (2015): Role of Chemotherapeutic Agents in the Management of Cystic Echinococcosis. Int Surg, 100(1): 112 \u2013 114. DOI: 10.9738\/INTSURG-D-14-00068.1","DOI":"10.9738\/INTSURG-D-14-00068.1"},{"key":"2026042808552310174_j_helm-2023-0028_ref_019","doi-asserted-by":"crossref","unstructured":"Nunnari, G., Pinzone, M. R, Gruttadauria, S., Celesia, B. M, Madeddu, G., Malaguarnera, G, Pavone, P., Cappellani, A., Cacopardo, B. (2012): Hepatic echinococcosis: clinical and therapeutic aspects. World J Gastroenterol, 18(13): 1448 \u2013 1458. DOI: 10.3748\/wjg.v18.i13.1448","DOI":"10.3748\/wjg.v18.i13.1448"},{"key":"2026042808552310174_j_helm-2023-0028_ref_020","doi-asserted-by":"crossref","unstructured":"Rainova, I.G., Harizanov, R.N., Tsvetkova, N.D., Kaftandjiev, I.T., Enikova, R.B., Ivanova, M., Videnova, M.V., Kaneva, E.M., Mikov, O.D. (2022): Epidemiological Indicators of the State of Cystic Echinococcosis in Republic of Bulgaria for the Period 2011 \u2013 2020. Int J Echinococcoses, 1(2): 26 \u2013 32. DOI: 10.5455\/IJE.2022.03.05","DOI":"10.5455\/IJE.2022.03.05"},{"key":"2026042808552310174_j_helm-2023-0028_ref_021","doi-asserted-by":"crossref","unstructured":"Salinas, J., Gonzales, H., Astuvilca, J., Arce-Villavicencio, Y., Carbajal-Gonzalez, D., Talledo, L., Willig, J.H. (2011): Long-term albendazole effectiveness for hepatic cystic echinococcosis. Am J Trop Med Hyg, 85(6): 1075 \u2013 1079; DOI: 10.4269\/ajtmh.2011.11-0382","DOI":"10.4269\/ajtmh.2011.11-0382"},{"key":"2026042808552310174_j_helm-2023-0028_ref_022","doi-asserted-by":"crossref","unstructured":"Smego, R.A., Sebanego, P. (2005): Treatment options for hepatic cystic echinococcosis. Int J Infect Dis, 9(2): 69 \u2013 76. DOI: 10.1016\/j.ijid.2004.08.001","DOI":"10.1016\/j.ijid.2004.08.001"},{"key":"2026042808552310174_j_helm-2023-0028_ref_023","doi-asserted-by":"crossref","unstructured":"Stojkovi\u0107, M., Weber, T., Junghanss, T. (2018): Clinical management of cystic echinococcosis: state of the art and perspectives. Curr Opin Infect Dis, 31(5): 383 \u2013 392. DOI: 10.1097\/QCO.0000000000000485","DOI":"10.1097\/QCO.0000000000000485"},{"key":"2026042808552310174_j_helm-2023-0028_ref_024","doi-asserted-by":"crossref","unstructured":"Velasco-Tirado, V., Alonso-Sard\u00f3n, M., Lopez-Bernus, A., Romero-Alegr\u00eda, \u00c1., Javier Burguillo, F.J., Muro, A., Carpio-P\u00e9rez, A., Mu\u00f1oz Bellido, J.L., Pardo-Lledias, J., Cordero, M. et al. (2018): Medical treatment of cystic echinococcosis: systematic review and meta-analysis. BMC Infect Dis, 18(1): 306. DOI: 10.1186\/s12879-018-3201-y","DOI":"10.1186\/s12879-018-3201-y"},{"key":"2026042808552310174_j_helm-2023-0028_ref_025","doi-asserted-by":"crossref","unstructured":"Vuitton, D.A. (2009): Benzimidazoles for the treatment of cystic and alveolar echinococcosis: what is the consensus? Expert Rev Anti Infect Ther, 7(2): 145 \u2013 149. DOI: 10.1586\/14787210.7.2.145","DOI":"10.1586\/14787210.7.2.145"},{"key":"2026042808552310174_j_helm-2023-0028_ref_026","doi-asserted-by":"crossref","unstructured":"Wen, H., Vuitton, L., Tuxun, T., Li, J., Vuitton, D.A., Zhang, W., McManus, D.P. (2019): Echinococcosis: advances in the 21st century. Clin Microbiol Rev, 32(2): e00075\u201318. DOI: 10.1128\/CMR.00075-18","DOI":"10.1128\/CMR.00075-18"},{"key":"2026042808552310174_j_helm-2023-0028_ref_027","unstructured":"WHO Informal Working Group on Echinococcosis. (1996): Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull WHO, 74: 231 \u2013 242"},{"key":"2026042808552310174_j_helm-2023-0028_ref_028","doi-asserted-by":"crossref","unstructured":"WHO Informal Working Group on Echinococcosis. (2003): International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings. Acta Trop, 85(2): 253 \u2013 261. DOI: 10.1016\/s0001-706x(02)00223-1","DOI":"10.1016\/S0001-706X(02)00223-1"}],"container-title":["Helminthologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/helm-2023-0028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:47:26Z","timestamp":1777394846000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/helm-2023-0028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,12,26]]},"published-print":{"date-parts":[[2023,9,1]]}},"alternative-id":["10.2478\/helm-2023-0028"],"URL":"https:\/\/doi.org\/10.2478\/helm-2023-0028","relation":{},"ISSN":["1336-9083"],"issn-type":[{"value":"1336-9083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}